IBEF Research: Ranbaxy Laboratories Limited

RELATED NEWS Ranbaxy signs licensing agreement with Debiopharm Ranbaxy Q3 pat up 651% at Rs 1404 mn Not eyeing any acquisition in France: Ranbaxy Ranbaxy's revenue growth to be led by Terapia acquisition RLL receives approval to commercialize Furosemide tablets ALSO READ See latest News about Ranbaxy Labs See previous management interviews See what other Experts & Brokerages are saying about Ranbaxy Labs Ranbaxy Labs BSE | NSE 10/02/12 Are Mutual Funds betting on Ranbaxy Labs?

Ranbaxy brief overview

Ranbaxy Laboratories Limited , India's largest pharmaceutical company, headquartered in India, is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. It is ranked amongst the top ten generic companies worldwide. The Company has manufacturing operations in 8 countries with a ground presence in 49 countries and its products are available in over 125 countries.

Ranbaxy was incorporated in 1961 and went public in 1973. For the twelve months ended December 31, 2005, the Company's Global Sales were at US $1178 Mn. Overseas markets accounted for over 75% of global sales. The Company's largest market USA with the sales of US $ 328 Mn, accounted for 28%, while Europe and BRIC (Brazil, Russia, India, China) countries contributed 17% and 29% to global sales.

Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies", resulting in a number of products under development.

Ranbaxy views its R&D capabilities as a vital component of its business strategy that will provide the company with a sustainable, long-term competitive advantage. The company today has a pool of 1,100 scientists who are engaged in path-breaking research.

contd on page 2...